Drug intelligence / Profile preview

placebo + methotrexate

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Subcutaneous, Intravenous

Overview

This is a combination of a placebo (an inert substance with no therapeutic effect) and methotrexate, an antimetabolite and immunosuppressant drug. Methotrexate inhibits dihydrofolate reductase, interfering with DNA synthesis, repair, and cellular replication. It is used to treat various cancers (such as leukemia, breast cancer, non-Hodgkin's lymphoma), severe psoriasis, rheumatoid arthritis, juvenile idiopathic arthritis, and other autoimmune or inflammatory conditions. The addition of placebo in clinical trials serves as a control to assess the efficacy and safety of methotrexate by comparison.

Other names: placeboplacebo plus methotrexate

Targets

DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on placebo + methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on placebo + methotrexate.

Explore the full profile